Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer

[1]  M. Kerin,et al.  Role of micro‐RNAs in breast cancer surgery , 2018, The British journal of surgery.

[2]  Artemis G. Hatzigeorgiou,et al.  DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA–gene interactions , 2017, Nucleic Acids Res..

[3]  S. Góźdź,et al.  Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. , 2017, Translational research : the journal of laboratory and clinical medicine.

[4]  Chuang Chen,et al.  Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study , 2017, Oncotarget.

[5]  S. Shak,et al.  West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[7]  K. Kuliczkowski,et al.  Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia , 2016, Oncology letters.

[8]  D. Levy,et al.  Discordant Expression of Circulating microRNA from Cellular and Extracellular Sources , 2016, PloS one.

[9]  Mark Gerstein,et al.  Diverse human extracellular RNAs are widely detected in human plasma , 2016, Nature Communications.

[10]  Dejia Li,et al.  Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer , 2016, Oncotarget.

[11]  M. Kerin,et al.  Exploring circulating micro‐RNA in the neoadjuvant treatment of breast cancer , 2016, International journal of cancer.

[12]  N. Saini,et al.  MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 , 2015, Scientific Reports.

[13]  J. Olson,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[14]  M. Dowsett,et al.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.

[15]  Xiaomin Wang,et al.  The roles of microRNAs in the regulation of tumor metastasis , 2015, Cell & Bioscience.

[16]  Mårten Fernö,et al.  Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease , 2015, EMBO molecular medicine.

[17]  P. Huang,et al.  MicroRNA-181 functions as a tumor suppressor in non-small cell lung cancer (NSCLC) by targeting Bcl-2 , 2015, Tumor Biology.

[18]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[19]  M. Kerin,et al.  Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring , 2015, Cancer and Metastasis Reviews.

[20]  G. Schmidt,et al.  Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase , 2015, British Journal of Cancer.

[21]  W. Wu,et al.  By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth , 2015, OncoTarget.

[22]  Jiang-feng Xu,et al.  MicroRNA‐331‐3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine‐rich repeat protein phosphatase , 2014, Hepatology.

[23]  G. Hortobagyi,et al.  Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination , 2014, Breast Cancer Research.

[24]  O. Yersal,et al.  Biological subtypes of breast cancer: Prognostic and therapeutic implications. , 2014, World journal of clinical oncology.

[25]  J. Gu,et al.  MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1 , 2014, Molecular Cancer.

[26]  Hongyang Zhao,et al.  miR‐329 suppresses the growth and motility of neuroblastoma by targeting KDM1A , 2014, FEBS letters.

[27]  A. McDermott,et al.  Identification and Validation of miRNAs as Endogenous Controls for RQ-PCR in Blood Specimens for Breast Cancer Studies , 2013, PloS one.

[28]  J. Lebrun,et al.  Activin and TGFβ regulate expression of the microRNA-181 family to promote cell migration and invasion in breast cancer cells. , 2013, Cellular Signalling.

[29]  O. Wolkenhauer,et al.  Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma , 2013, Oncogene.

[30]  M. Lux,et al.  Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. , 2013, European journal of cancer.

[31]  Axel Benner,et al.  Circulating microRNAs in plasma as early detection markers for breast cancer , 2013, International journal of cancer.

[32]  William P Schiemann,et al.  TGF-β upregulates miR-181a expression to promote breast cancer metastasis. , 2013, The Journal of clinical investigation.

[33]  M. Tewari,et al.  MicroRNA profiling: approaches and considerations , 2012, Nature Reviews Genetics.

[34]  N. Saini,et al.  Downregulation of BCL2 by miRNAs augments drug-induced apoptosis – a combined computational and experimental approach , 2012, Journal of Cell Science.

[35]  Xiangyi Zheng,et al.  Cyclin‐dependent kinase 4 is a novel target in micoRNA‐195‐mediated cell cycle arrest in bladder cancer cells , 2012, FEBS letters.

[36]  H. Rui,et al.  Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer , 2011, Clinical Cancer Research.

[37]  Denis Evoy,et al.  CA 15-3: uses and limitation as a biomarker for breast cancer. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[38]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[39]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[40]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[42]  J. Yun,et al.  MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells , 2009, Hepatology.

[43]  H. Nielsen,et al.  National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. , 2008, Clinical chemistry.

[44]  Emma M. Petty,et al.  MicroRNAs in development and disease , 2008, Clinical genetics.

[45]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[46]  H. Giese,et al.  Efficient four fragment cloning for the construction of vectors for targeted gene replacement in filamentous fungi , 2008, BMC Molecular Biology.

[47]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2007, Nature.

[48]  George P Cobb,et al.  microRNAs as oncogenes and tumor suppressors. , 2007, Developmental biology.

[49]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[50]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[51]  A. Nicolini,et al.  "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. , 2003, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[52]  C. Sweep,et al.  Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.

[53]  B. Park,et al.  Circulating Plasma Tumor DNA. , 2016, Advances in experimental medicine and biology.

[54]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .